-
Brazil patient groups challenge Conitec rules on civil society participation
Brasília – Patient organizations in Brazil are preparing legal action against current rules of the National Committee for Health Technology Incorporation (Conitec), arguing that recent regulations fail to ensure effective participation of civil society in decision-making on technology incorporation into the public health system. The initiative is led by Casa Hunter, which claims that restrictions…
-
Brazilian Ministry of Health plans to launch new drug procurement model in 2026
Brasília – The federal government is preparing to implement a new model for the procurement of drugs within the Unified Health System (SUS) starting in 2026, aiming to increase efficiency and reduce costs through more strategic purchasing mechanisms. The proposal includes leveraging Brazil’s large purchasing volume to negotiate lower prices, particularly for high-cost and complex…
-
Brazil to test lung cancer screening program in public health system
Brasília – The National Cancer Institute (INCA) announces a pilot study to evaluate the feasibility of implementing a lung cancer screening program within the Unified Health System (SUS). Conducted in partnership with the Rio de Janeiro municipal health authority and supported by AstraZeneca, the initiative aims to generate evidence for a future national guideline focused…
-
Brazil seen as priority market for Novo Nordisk’s oral Wegovy
Brasília – Novo Nordisk identifies Brazil as a priority market for the launch of its oral version of Wegovy, a semaglutide-based treatment for obesity, as the company seeks to expand its footprint in one of the world’s fastest-growing weight management markets. The tablet formulation, already submitted to the National Health Surveillance Agency (ANVISA), is expected…
-
Brazil’s CMED fines drug distributors and defends stricter regulation
Brasília – The Drug Market Regulation Chamber (CMED) imposes more than BRL 13.5 million in fines on pharmaceutical distributors for offering medicines above regulated price ceilings, reinforcing its stance on stricter market oversight. Sanctioned companies include Imediata Distribuidora de Produtos para a Saúde, Fabmed Distribuidora Hospitalar, Panorama Comércio de Produtos Médicos e Farmacêuticos, and Realmed…
PHARMABR WEEKLY
Get weekly insights from Brazil’s health sector
